AL SB299

Permits licensed physicians to perform non-FDA-approved stem cell therapy if they provide patients written notice about the nature, anticipated results, and recognized risks, and obtain signed patient consent.

Requires providers offering stem cell therapy to prominently display an 8.5" by 11" notice in at least 40-point type in office entrances and include the notice in all advertisements stating the therapy is not FDA-approved.

Defines stem cell therapy to include afterbirth placental perinatal stem cells and human cellular or tissue-based products, but excludes treatments derived from aborted fetus or embryo tissue.

Exempts therapies with FDA investigational approval and therapies performed under employment or contract with institutions certified by specified accreditation organizations or the State Board of Medical Examiners.

Classifies violations as unprofessional conduct subject to licensure penalties; requires the State Board of Medical Examiners to adopt implementing rules; becomes effective October 1, 2025.